Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?
- 30 April 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (6) , 954-964
- https://doi.org/10.1016/j.ejca.2005.02.002
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Antisense approaches in prostate cancerExpert Opinion on Biological Therapy, 2004
- 577. MVA-MUC1-IL2 Vaccine Immunotherapy for Patients Post-Prostatectomy with Rising PSA and No Evident MetastasesMolecular Therapy, 2004
- Introduction of Clusterin Gene into Human Renal Cell Carcinoma Cells Enhances Their Resistance to Cytotoxic Chemotherapy through Inhibition of Apoptosis both in vitro and in vivoJapanese Journal of Cancer Research, 2001
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- Docetaxel and exisulind in hormone-refractory prostate cancerSeminars in Oncology, 2001
- Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancerSeminars in Oncology, 2001
- ANGIOGENESIS IN TWO HUMAN PROSTATE CANCER CELL LINES WITH DIFFERING METASTATIC POTENTIAL WHEN GROWING AS SOLID TUMORS IN NUDE MICEJournal of Urology, 1998
- Overexpression of her-2/neu in human prostate cancer and benign hyperplasiaCancer Letters, 1996
- Non-hypercalcemic pharmacological aspects of vitamin D analogsBiochemical Pharmacology, 1995
- Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3Endocrinology, 1995